

TIDES® Agenda-at-a-Glance

Sunday, April 25, 2010

9:00 am - 1:00 pm	Course #1: Current Topics in Oligonucleotide Manufacturing		Course #2: Bioanalytical Methods for the Determination of Therapeutic Oligonucleotides	
2:00 pm - 6:00 pm	Course #3: Current Topics in the Analysis of Oligonucleotides in Support of Drug Development	Course #4: Managing Analytical Development and Quality Control for Peptides		Course #5: Oligonucleotide Lead Discovery and Candidate Selection
6:00 pm - 7:00 pm	Welcoming Reception for Course Attendees Sponsored by Avecia OligoMedicines and Alnylam			

Monday, April 26, 2010

Exhibit Hall/Poster Hours: 5:15 pm - 6:45 pm

8:30 am - 11:00 am	<p>Keynote Presentations: Open to TIDES® and Oligo Therapeutics Discovery Delegates</p> <p>Synthetic Biologics: A New Class of Drugs for "Undruggable" Targets, Gregory L. Verdine, Ph.D., <i>Erving Professor of Chemistry, Harvard University</i></p> <p>RNAi: Developing a New Therapeutic Platform, John Maraganore, Ph.D., <i>Chief Executive Officer, Alnylam Pharmaceuticals, Inc.</i></p> <p>Non-Coding RNAs as Drug Targets, Claes R. Wahlestedt, M.D., Ph.D., <i>Professor, Director of Neuroscience Discovery, The Scripps Research Institute - Florida</i></p>			
11:30 am - 12:30 pm	<p>TIDES Main Conference Featured Presentations</p> <p>Deal Trends in Nucleic Acid Based Therapeutics: A Look at Past Deals and Thoughts on the Future Philip McGurk, Ph.D., <i>Senior Director, Business Development, Pfizer Inc.</i></p> <p>Update on Peptide Therapeutics Market Outlook Janice M. Reichert, Ph.D., <i>Senior Research Fellow, Tufts Center for the Study of Drug Development;</i> <i>Editor-in-Chief, mAbs, Landes Biosciences</i></p>			<p>Oligonucleotide Therapeutics Discovery Conference</p> <p>What Are We Looking for from Oligonucleotide Therapeutics? Preclinical Chemical Modifications to Improve Drug-Like Properties (Session time: 11:30 am - 1:05 pm. Lunch on your own: 1:05 pm - 2:15 pm)</p>
12:00 pm - 4:00 pm	Site Tour to Avecia OligoMedicines			
12:30 pm - 2:00 pm	Lunch on your own			
	Oligonucleotides	Peptides	Break-Out Discussion Sessions	Preclinical Chemical Modifications
2:00 pm - 5:15 pm	Regulatory Updates for Oligonucleotides and Peptides		Late-Breaking Industry Issues	
5:15 pm - 6:45 pm	Networking Cocktail Reception, Opening of Poster and Exhibit Hall			

Tuesday, April 27, 2010

Exhibit Hall/Poster Hours: 9:30 am - 6:15 pm

	Oligonucleotides	Peptides	Break-Out Discussion Sessions	Applications of Nucleic Acids Technologies for Molecular Diagnostics	Oligonucleotide Therapeutics Discovery Conference
8:00 am - 9:30 am	<p>Innovation Showcase 9:00 Presentation Sponsored by TransPharma Medical</p>		<p>Regulatory Updates Follow up Discussions 8:00 - 8:45 Oligos 8:45 - 9:30 Peptides</p>	<p>Regulatory Pathways and Quality Strategies</p> <p>Keynote Presentations: Commercialization of IVDs Labeled for Research Use Only or Investigational Use Only Elizabeth Mansfield, Ph.D., <i>Director for Personalized Medicine, OIVD, CDRH, US FDA</i></p> <p>Challenges in Drug and Diagnostic Co-Development - A Diagnostic Perspective William Pignato, <i>Global Head, Regulatory Affairs, Novartis Molecular Diagnostics</i></p>	<p>Overcoming Cellular Barriers to siRNA Delivery</p> <p>Understanding Preclinical Toxicology of Oligonucleotides</p>
10:15 am - 12:30 pm	<p>CMC: Manufacturing and Analysis 11:30 Technology Workshop Sponsored by Girindus America Inc. Member of Solvay Organics</p>	<p>CMC: Manufacturing and Analysis</p>			
12:30 pm - 1:45 pm	Networking Luncheon, Exhibit and Poster Viewing in Exhibit Hall sponsored by Lonza				
1:45 pm - 5:15 pm	<p>CMC: Manufacturing and Analysis 3:45 Technology Workshop Sponsored by Agilent Technologies</p>	<p>CMC: Manufacturing and Analysis 2:15 Technology Workshop Sponsored by Bruker Daltonics</p>		<p>Manufacturing and Business Considerations for Successful Launch in Clinical Market</p>	<p>Preclinical/Clinical Case Studies</p>
5:15 pm - 6:15 pm	Networking Cocktail Reception, Exhibit and Dedicated Poster Viewing				

Wednesday, April 28, 2010

Exhibit Hall/Poster Hours: 9:45 am - 1:30 pm

	Oligonucleotides	Peptides	Break-Out Discussion Sessions	Applications of Nucleic Acids Technologies for Molecular Diagnostics	Oligonucleotide Therapeutics Discovery Conference
8:00 am - 9:45 am	Formulation and Delivery	<p>Formulation and Delivery 9:45 Follow Up Roundtable Discussion to Peptide CMC Session</p>	<p>Follow Up Discussion to Oligo CMC Session</p>	Analytical Methods and Validation	<p>Formulation and Delivery Shared w/TIDES® Oligo Track</p>
10:15 am - 12:15 pm	Formulation and Delivery	Formulation and Delivery	<p>10:15 Applications of Mass Spectrometry to Synthetic Oligonucleotides 11:15 Intellectual Property Issues</p>	<p>Analytical Methods and Validation (continued) New Technologies</p>	<p>Formulation and Delivery Shared w/TIDES® Oligo Track</p>
12:15 pm - 1:30 pm	Networking Luncheon, Final Opportunity for Exhibit and Poster Viewing in Exhibit Hall				
1:30 pm - 4:30 pm	Site Tour to Alnylam Pharmaceuticals				
1:30 pm - 5:15 pm	<p>Updates on Compounds in Preclinical and Clinical Development</p>	<p>Updates on Compounds in Preclinical and Clinical Development</p>	<p>1:30 pm - 3:00 pm Peptide Impurities</p>	New Technologies	<p>Updates on Compounds in Preclinical and Clinical Development Shared w/TIDES® Oligo Track</p>

Visit www.IBCLifeSciences.com/TIDES for up-to-date information on this event